Zejing Pharmaceutical announced that the clinical research data and latest developments of the new drugs ZG005 and ZGGS18 independently developed by the company will be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. ZG005 is one of the world's first same-target drugs to enter clinical research. Currently, no drug with a similar mechanism has been approved for marketing worldwide. A phase I/II clinical study of ZG005 in patients with advanced solid tumors showed that initial results showed better efficacy, especially in advanced cervical cancer patients receiving a dose of 20 mg/kg. Phase I/II clinical studies of ZGGS18 in advanced solid tumor patients also showed good tolerability, safety, and anti-tumor efficacy.